GeoVax Labs reports third quarter net loss and lower revenue

Reuters

11/14

GeoVax Labs reports third quarter net loss and lower revenue

GeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583510798"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583510798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583510798?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583510798","market":"us","top_or_hot":-1,"title":"GeoVax Labs reports third quarter net loss and lower revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeoVax Labs reports third quarter net loss and lower revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GOVX\">GeoVax Labs Inc</a>. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOVXW\">GeoVax Labs Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeoVax Labs reports third quarter net loss and lower revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeoVax Labs reports third quarter net loss and lower revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-14 06:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeoVax Labs reports third quarter net loss and lower revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GOVX\">GeoVax Labs Inc</a>. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOVXW\">GeoVax Labs Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3mxvYY:1","article_id":"2583510798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583510798","pubTimestamp":1763072494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4139":"生物科技","GOVX":"GeoVax Labs Inc"},"translate_title":"GeoVax Labs报告第三季度净亏损和收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOVX":0.9},"content_text":"GeoVax Labs reports third quarter net loss and lower revenue\n    \n\nGeoVax Labs Inc. reported a net loss of $6.3 million, or $0.31 per share, for the third quarter ended September 30, 2025, compared to a net loss of $5.8 million, or $0.91 per share, for the same period in 2024. For the nine-month period, the net loss was $17.0 million, or $0.97 per share, versus $16.7 million, or $4.5 per share, in 2024. The company reported no revenue for the third quarter and $2.5 million in government contract revenues for the nine months, compared to $2.8 million and $3.1 million, respectively, in the prior year. GeoVax's cash balance was $5.0 million as of September 30, 2025, down from $5.5 million at the end of 2024. Key business developments included the acceleration of the GEO-MVA program in response to the global Mpox emergency, expansion of the Gedeptin program into new solid tumor indications, and positive clinical data from the GEO-CM04S1 trial in immunocompromised patients. The company also noted the termination of its BARDA contract in April 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034903), on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}